Clarivate Epidemiology’s coverage of acute heart failure (AHF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the hospitalization rate of AHF…
MARKET OUTLOOK Age-related macular degeneration (AMD) is a leading cause of visual impairment in the United States, and more than half of advanced AMD patients have the wet (exudative, neovascular…
Psoriasis is a chronic, inflammatory, autoimmune skin disease that can affect children, adolescents, and adults. Although adult psoriasis and pediatric psoriasis are similar, effective management…
According to Clarivate epidemiology, more than 30 million people in the United States suffer from migraines. Despite being underused, migraine prophylaxis is a core treatment approach to reduce the…
The primary goal of hemophilia A treatment is to prevent bleeding. Hemophilia A patients are a heterogeneous cohort; the tendency to bleed is highly individual. Currently available treatments…
MARKET OVERVIEW Chronic hand eczema (CHE) is a painful and debilitating form of eczema localized to the hands that can seriously impact a patient’s quality of life. No prescription therapies are…
The oral type 2 diabetes (T2D) drug market is expected to grow, fueled by rising prevalence and an increasing aging population. Owing to the risk of proteinuria, cardiovascular (CV) complications,…
Eosinophilic esophagitis (EoE) is a chronic, allergic inflammatory disease of the esophagus, characterized by an accumulation of eosinophils. It can cause difficulty in swallowing food and the…
Non-small-cell lung cancer (NSCLC), a dynamic oncology indication with high unmet need, remains a key area of focus for drug developers. NSCLC is defined by driver mutations, and treatment is…
Rheumatoid arthritis (RA) patients who are refractory to one or more tumor necrosis factor-alpha (TNF-α) inhibitors are generally prescribed a non-TNF targeted therapy (e.g., Bristol Myers Squibb…
For the past decade, Erbitux-based regimens have been the mainstay of treatment for recurrent or metastatic non-nasopharyngeal squamous cell carcinoma of the head and neck (SCCHN), but the launches…
TNF-α inhibitors (AbbVie’s Humira, Amgen’s Enbrel, Janssen’s Remicade and Simponi, UCB’s Cimzia) are approved for the treatment of nonradiographic axial spondyloarthritis (nr-AxSpA) in…
TNF-α inhibitors (AbbVie’s Humira, Amgen’s Enbrel, Janssen’s Remicade and Simponi, UCB’s Cimzia) are approved for the treatment of nonradiographic axial spondyloarthritis (nr-AxSpA) in…
The multiple sclerosis (MS) therapy market continues to evolve with each new FDA-approved disease-modifying therapy (DMT) further expanding treatment choice. The newest entrants (e.g., Kesimpta,…
MARKET OUTLOOK Idiopathic pulmonary fibrosis (IPF) is an orphan disease affecting approximately 50,000 people in the United States. It is characterized by an irreversible loss of lung function,…